Fortress Biotech Inc. buy melinda
Start price
30.08.18
/
50%
€1.81
Target price
17.12.18
€3.61
Performance (%)
-48.76%
End price
17.12.18
€0.93
Summary
This prediction ended on 17.12.18 with a price of €0.93. Massive losses of -48.76% were the result for the BUY prediction by melinda. melinda has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Fortress Biotech Inc. | - | - | - | - |
iShares Core DAX® | 0.000% | -2.064% | 13.111% | 16.685% |
iShares Nasdaq 100 | 0.626% | -2.884% | 37.744% | 43.441% |
iShares Nikkei 225® | 1.568% | -5.892% | 19.592% | 4.617% |
iShares S&P 500 | 0.334% | -2.281% | 27.745% | 41.046% |
Comments by melinda for this prediction
In the thread Fortress Biotech Inc. diskutieren
SecteurProduits pharmaceutiques Agenda 08/11 Publication de résultats
Develops novel immunotherapy biologic agents
Fortress Biotech, Inc. engages in the development and commercialization of novel pharmaceutical and biotechnology products.
It operates through the following segments: Dermatology Product Sales, Pharmaceutical and Biotechnology Product Development, and National.
The National segment consists of National Holdings Corporation, an independent brokerage company.
The company was founded on June 28, 2006 in and is headquartered in New York, NY.
Fortress Biotech, Inc. engages in the development and commercialization of novel pharmaceutical and biotechnology products.
It operates through the following segments: Dermatology Product Sales, Pharmaceutical and Biotechnology Product Development, and National.
The National segment consists of National Holdings Corporation, an independent brokerage company.
The company was founded on June 28, 2006 in and is headquartered in New York, NY.
Nombre d'employés : 68 personnes.
(Vom Mitglied beendet)